title: [Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts].
abstract: Recombinant factor VIIa (rFVIIa; NovoSeven) is, besides other indications, authorised for the treatment of bleeding episodes in patients with hereditary haemophilia A or B and inhibitors. Based on the results of three clinical studies, marketing authorisation was granted for the single dose of 270 microg/kg body weight rFVIIa for the treatment of mild to moderate bleeding episodes in patients with haemophilia A or B with inhibitors in March 2007. Thereupon, an expert group analysed the relevance of this additional treatment option for clinical routine. Compared with the repeated application of 90 microg/kg body weight rFVIIa, quality of life may be improved if the single dose of 270 microg/kg body weight rFVIIa reduces the number of injections. The single dose has a benefit for those patients who require several rFVIIa applications or who do not respond adequately to low doses. Moreover, patients with poor venous access or patients who fear injections or reject them (especially children) may benefit from the single dose. The prescription of 270 microg/kg body weight rFVIIa as a single dose instead of multiple dosing of 90 microg/kg body weight is basically an individual and indication-related decision.
authors.affiliation: Zentrum für Kinder- und Jugendheilkunde, Klinikum Bremen-Mitte, Professor-Hess-Kinderklinik, 28205 Bremen, Germany. guenterauerswald@aol.com.
authors.forename: Günter
authors.initials: G
authors.lastname: Auerswald
authors.forename: W
authors.initials: W
authors.lastname: Muntean
authors.forename: B
authors.initials: B
authors.lastname: Kemkes-Matthes
authors.forename: R
authors.initials: R
authors.lastname: Klamroth
authors.forename: M
authors.initials: M
authors.lastname: Krause
authors.forename: K
authors.initials: K
authors.lastname: Kurnik
authors.forename: J
authors.initials: J
authors.lastname: Oldenburg
authors.forename: I
authors.initials: I
authors.lastname: Pabinger-Fasching
authors.forename: W
authors.initials: W
authors.lastname: Schramm
authors.forename: R
authors.initials: R
authors.lastname: Zimmermann
authors.forename: R B
authors.initials: RB
authors.lastname: Zotz
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D015942:Factor VIIa / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*; D005260:Female; D006467:Hemophilia A / Q000188:drug therapy*; D002836:Hemophilia B / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013923:Thromboembolism / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D011994:Recombinant Proteins; D015942:Factor VIIa